Trial · NCT07487948
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
NCT07487948, Phase 2, Recruiting, Icahn School of Medicine at Mount Sinai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris. Trials, record NCT07487948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07487948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
- NCT number
- NCT07487948
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
- Interventions
- Delgocitinib
- First posted
- 2026-03-23
- Last updated
- 2026-07-10
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in IFNγ in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes in CCL5 in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes CXCL9 markers in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Primary | Changes in CXCL10 in CA scalp in delgocitinib-treated patients | Baseline to Week 36 | Changes in Th1 markers in CA scalp from baseline to week 36 in delgocitinib-treated patients |
| Secondary | Changes in IFNγ in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in CCL5 in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in CXCL9 in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in Th1 markersCXCL10in CA scalp in delgocitinib-treated patients | Week 36 to Week 48 | Changes in Th1 markers in CA scalp from baseline to week 48 and from week 36 to week 48 |
| Secondary | Changes in TGFB1/2 | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
| Secondary | Changes in vimentin | Baseline to Week 36; Baseline to Week 48 | Changes in biomarkers of fibrosis at weeks 36 and at weeks 48 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07487948
GET https://conductscience.org/api/trials/v1/NCT07487948/registered?page=2